<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39364854</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-764X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>08</Day></PubDate></JournalIssue><Title>Expert opinion on drug safety</Title><ISOAbbreviation>Expert Opin Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Safety considerations for drugs newly approved for treating acute myeloid leukemia.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>12</EndPage><MedlinePgn>1-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/14740338.2024.2412236</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Acute myeloid leukemia (AML) is typically characterized by a poor prognosis, mainly due to the median age at diagnosis. Until recently, treatment options were limited to intensive chemotherapy (IC) for young patients or hypomethylating agents for those ineligible for IC. Since 2017, nine molecules were registered for newly-diagnosed AML: midostaurin, gilteritinib, quizartinib, enasidenib, ivosidenib, gemtuzumab ozogamicin, CPX-351, glasdegib, and venetoclax.</AbstractText><AbstractText Label="AREAS COVERED" NlmCategory="UNASSIGNED">The review examines the safety profile of these drugs and their interactions with other agents used in supportive care. The PubMed and Google Scholar databases were searched for articles in English concerning new agents in AML from 2017 until 2023. Further relevant publications were obtained by reviewing the prescribing information and Food and Drug Administration (FDA) data.</AbstractText><AbstractText Label="EXPERT OPINION" NlmCategory="UNASSIGNED">The therapeutic spectrum in AML has broadened over several years and can also improve outcomes in older patients. However, in addition to their well-known cytotoxic activity, new molecules cause several unique, off-target toxicities. Also, potential drug-drug interactions (DDI) should be taken into consideration when choosing optimal first-line therapy; this remains a challenge in clinical practice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gołos</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7780-3587</Identifier><AffiliationInfo><Affiliation>Department of Hematology, Medical University of Lodz, Lodz, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Hematooncology, Copernicus Memorial Hospital, Lodz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Góra-Tybor</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6427-4532</Identifier><AffiliationInfo><Affiliation>Department of Hematology, Medical University of Lodz, Lodz, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Hematooncology, Copernicus Memorial Hospital, Lodz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robak</LastName><ForeName>Tadeusz</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-3411-6357</Identifier><AffiliationInfo><Affiliation>Department of Hematology, Medical University of Lodz, Lodz, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Hematology, Copernicus Memorial Hospital, Lodz, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Drug Saf</MedlineTA><NlmUniqueID>101163027</NlmUniqueID><ISSNLinking>1474-0338</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AML</Keyword><Keyword MajorTopicYN="N">CPX-351</Keyword><Keyword MajorTopicYN="N">FLT3 inhibitors, IDH inhibitors</Keyword><Keyword MajorTopicYN="N">gemtuzumab ozogamicin</Keyword><Keyword MajorTopicYN="N">glasdegib</Keyword><Keyword MajorTopicYN="N">venetoclax</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>7</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39364854</ArticleId><ArticleId IdType="doi">10.1080/14740338.2024.2412236</ArticleId></ArticleIdList></PubmedData></PubmedArticle>